Table 1.

Demographics and timing of laboratory abnormalities per medication.

	Infliximab	Adalimumab	Etanercept	Golimumab
Number of patients	22	17	4	2
Age in years, median (range)	39.5 (20–78)	33 (19–73)	51.5 (29–73)	55.5 (43–68)
Male: Female	6: 16	6: 11	1: 3	1: 1
Diagnosis
Hidradenitis suppurativa	11	12	0	0
Pyoderma gangrenosum	6	1	1	0
Psoriasis/psoriatic arthritis	5	4	3	2
Exposure to drug in months, median (range)	6.1 (3.6–57.8)*	19.3 (3.3–89.7)	5.2 (4.5–83.0)	24.1 (11.4–36.7)
Baseline abnormality	11	4	2	2
Resolved	5	1	1	2
Continued, duration in months	5	3	1	0
Duration in months, (range)	7.5 (3–48)	6 (6–18)	3
Discontinued drug due to abnormality	1β	0	0	0
Monitoring abnormality	1	5	0	1**
Resolved	1	5	0	1**
Continued in months, duration	0	0	0	0
Discontinued drug due to abnormality	0	0	0	0
Timing of abnormality
Baseline	11/12	4/9	2/2	2/2
After baseline and < 6 months	1/12	0	0	0
≥ 6 months and < 12 months	0	0	0	0
≥ 12 months and < 18 months	0	1/9	0	1**
≥ 18 months	0	4/9α	0	1**
Discontinued, n	7	15	3	2
No benefit	3	13	1	2
Allergy	2	1	0	0
Laboratory abnormality	1	0	0	0
Infection	0	1	1	0
Pregnant	1	0	0	0
Not stated	0	0	1	0

^*One patient discontinued at day 1 of infusion due to drug allergy.

^**This patient also had baseline abnormality that resolved. Patient had transient leukocytosis at 12, 24, and 36 months that all resolved at following laboratory draws.

^αTransient laboratory abnormalities at 18, 27, and 51 months.

^βPatient had chronic anemia that did not improve despite discontinuing infliximab.

Note: BL: baseline; Resolved, abnormality was not present by subsequent laboratory draw. Resolved abnormalities were not present at the following 3-month laboratory draw.